Covezzoli A - Search Results

1

Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.

Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Brock PR, et al. Among authors: covezzoli a. N Engl J Med. 2018 Jun 21;378(25):2376-2385. doi: 10.1056/NEJMoa1801109. N Engl J Med. 2018. PMID: 29924955 Free PMC article. Clinical Trial.

2

Disease management of the metabolic syndrome in a community: study design and process analysis on baseline data.

Melchionda N, Forlani G, La Rovere L, Argnani P, Trevisani F, Zocchi D, Savorani G, Covezzoli A, De Rosa M, Marchesini G. Melchionda N, et al. Among authors: covezzoli a. Metab Syndr Relat Disord. 2006 Spring;4(1):7-16. doi: 10.1089/met.2006.4.7. Metab Syndr Relat Disord. 2006. PMID: 18370765

3

Use of aliskiren in a 'real-life' model of hypertension management: analysis of national Web-based drug-monitoring system in Italy.

Volpe M, Tocci G, Bianchini F, De Rosa M, Fedozzi E, Covezzoli A, Maggioni AP; AIFA Drug Monitoring Program: Aliskiren Registry. Volpe M, et al. Among authors: covezzoli a. J Hypertens. 2012 Jan;30(1):194-203. doi: 10.1097/HJH.0b013e32834e1c66. J Hypertens. 2012. PMID: 22157325

4

Right heart thrombi in pulmonary embolism: results from the International Cooperative Pulmonary Embolism Registry.

Torbicki A, Galié N, Covezzoli A, Rossi E, De Rosa M, Goldhaber SZ; ICOPER Study Group. Torbicki A, et al. Among authors: covezzoli a. J Am Coll Cardiol. 2003 Jun 18;41(12):2245-51. doi: 10.1016/s0735-1097(03)00479-0. J Am Coll Cardiol. 2003. PMID: 12821255 Free article.

5

Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary Embolism Registry [ICOPER]).

McHugh KB, Visani L, DeRosa M, Covezzoli A, Rossi E, Goldhaber SZ. McHugh KB, et al. Among authors: covezzoli a. Am J Cardiol. 2002 Mar 1;89(5):616-9. doi: 10.1016/s0002-9149(01)02310-4. Am J Cardiol. 2002. PMID: 11867055 No abstract available.

6

The pharmacovigilance program on natalizumab in Italy: 2 years of experience.

Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL. Tedeschi G, et al. Among authors: covezzoli a. Neurol Sci. 2009 Oct;30 Suppl 2:S163-5. doi: 10.1007/s10072-009-0143-6. Neurol Sci. 2009. PMID: 19882367

7

Three years of experience: the Italian registry and safety data update.

Mancardi GL, Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Laroni A, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Iommelli R, Tomino C, Provinciali L. Mancardi GL, et al. Among authors: covezzoli a. Neurol Sci. 2011 Jan;31 Suppl 3:295-7. doi: 10.1007/s10072-010-0356-8. Neurol Sci. 2011. PMID: 20644975

8

Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): data from an Italian observational study in nephrology.

Motola D, Vaccheri A, Roncadori A, Donati M, Bonaldo G, Covezzoli A, Polidori P, Bianchi S. Motola D, et al. Among authors: covezzoli a. Eur J Clin Pharmacol. 2018 Jun;74(6):805-810. doi: 10.1007/s00228-018-2428-2. Epub 2018 Feb 10. Eur J Clin Pharmacol. 2018. PMID: 29429032

9

Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency.

Arcioni F, Roncadori A, Di Battista V, Tura S, Covezzoli A, Cundari S, Mecucci C; MORE Study Centres. Arcioni F, et al. Among authors: covezzoli a. Eur J Haematol. 2018 Jul;101(1):78-85. doi: 10.1111/ejh.13067. Epub 2018 May 22. Eur J Haematol. 2018. PMID: 29569278 Clinical Trial.

10

Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions.

Biagi C, Conti V, Montanaro N, Melis M, Buccellato E, Donati M, Covezzoli A, Amato R, Pazzi L, Venegoni M, Vaccheri A, Motola D. Biagi C, et al. Among authors: covezzoli a. Eur J Clin Pharmacol. 2014 Dec;70(12):1505-12. doi: 10.1007/s00228-014-1755-1. Epub 2014 Sep 20. Eur J Clin Pharmacol. 2014. PMID: 25234795

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page